Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers begin approved drugs screening for clinical use against rare diseases

Breakdown products of thalidomide cause birth defects: New study

Breakdown products of thalidomide cause birth defects: New study

Pitt, UPCI researchers' cancer studies presented at AACR meeting

Pitt, UPCI researchers' cancer studies presented at AACR meeting

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide provides new hope for patients with difficult to treat liver cancer

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Researchers create model that predicts drug effects on fetal development

Researchers create model that predicts drug effects on fetal development

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Drug to reverse immunological decline in aging

Drug to reverse immunological decline in aging

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

No overall cancer risk in people who donate stem cells

No overall cancer risk in people who donate stem cells

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor